An anti-IL-6 antibody or lentiviral-mediated RNAi against IL-6 in MSCs, the inhibition or knockdown of ET-1 in cancer cells, or the suppression of ERK and Akt in host endothelium cells can all be used to target the IL-6/ET-1/Akt or ERK pathway of tumor-stroma interaction. This evidence concerns the gene EDN1 and neoplasm.